Overview

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.
Phase:
Phase 4
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
University of Nottingham
Treatments:
(T,G)-A-L
Alemtuzumab
Cladribine
Dimethyl Fumarate
Fingolimod Hydrochloride
Glatiramer Acetate
Interferon-beta
Interferons
Natalizumab
Ocrelizumab
Ofatumumab
Ozanimod
Ponesimod
Rituximab
Siponimod
Teriflunomide